The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine

Tehrani, Narges Khabazzadeh; Mahdavi, Mehdi; Maleki, Fatemeh; Zarrati, Somayeh; Tabatabaie, Fatemeh

doi:10.1007/s12639-014-0574-8

Cited by 13 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Tehrani et al demonstrated the efficacy of thiol-specific antioxidant (TSA) antigen against Leishmania major using adjuvant Montanide ISA 70. In vivo immunization of BALB/c mice and challenge with Leishmania major revealed that specific IgG1 and IgG2a levels were elevated and vaccine-elicited humoral and cellular immune response [ 101 ]. Currently, Montanide™ adjuvanted vaccines, in particular ISA™51, against many diseases such as malaria, HIV, and various cancers are under different phases of clinical trials and have been reviewed in detail by van Doorn et al [ 102 ].…”

Section: Nanotechnology-based Vaccines Vaccine Adjuvants and Delivery Systemsmentioning

confidence: 99%

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

et al. 2021

View full text Add to dashboard Cite

The development of vaccines is one of the most significant medical accomplishments which has helped to eradicate a large number of diseases. It has undergone an evolutionary process from live attenuated pathogen vaccine to killed whole organisms or inactivated toxins (toxoids), each of them having its own advantages and disadvantages. The crucial parameters in vaccination are the generation of memory response and protection against infection, while an important aspect is the effective delivery of antigen in an intelligent manner to evoke a robust immune response. In this regard, nanotechnology is greatly contributing to developing efficient vaccine adjuvants and delivery systems. These can protect the encapsulated antigen from the host’s in-vivo environment and releasing it in a sustained manner to induce a long-lasting immunostimulatory effect. In view of this, the present review article summarizes nanoscale-based adjuvants and delivery vehicles such as viral vectors, virus-like particles and virosomes; non-viral vectors namely nanoemulsions, lipid nanocarriers, biodegradable and non-degradable nanoparticles, calcium phosphate nanoparticles, colloidally stable nanoparticles, proteosomes; and pattern recognition receptors covering c-type lectin receptors and toll-like receptors.

show abstract

Section: Nanotechnology-based Vaccines Vaccine Adjuvants and Delivery Systemsmentioning

confidence: 99%

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In nano-iCnB, the ZP was lower than that of nano-milliQW, demonstrating desirable physical characteristics for a W/O type emulsion vaccine formulation 20 . This suggests product stability, controlled release and stimulation of the immune response 18,23 .…”

Section: Discussionmentioning

confidence: 95%

Inactivated alpha toxin from Clostridium novyi type B in nano-emulsion protect partially protects Swiss mice from lethal alpha toxin challenge

Felix

Deusdará

Santos

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Nano-emulsions are promising carriers for antigen delivery. Here, we evaluated the efficacy of a water-oil nano-emulsion containing concentrated, inactivated Clostridium novyi (C. novyi) type B supernatant culture (nano-iCnB) in protecting Swiss mice against a lethal dose of alpha toxin concentrated extract. Proteins were confirmed in the nano-iCnB and their stabilities were determined according physical parameters such as Zeta Potential (ZP). Biochemical, hematological parameters and morphological appearance of liver, spleen and thigh muscle alterations were examined to determine the safety of the compound. Partial protection against lethal doses was achieved in immunized mice despite low IgG titers. These data suggest that our nano-emulsion is a simple and efficient method of promoting antigen delivery for toxin-related diseases.

show abstract

“…A sample of 100 µL was taken for electron microscopy scanning. The CFP booster formulations were prepared with 900 μL of CFP and 100 μL of adjuvant (Montanide TM ) and oil-based adjuvant composed of a natural metabolizable oil and a highly refined emulsifier from the manide monooleate family [ 59 ].…”

Section: Methodsmentioning

confidence: 99%

Prime Vaccination with Chitosan-Coated Phipps BCG and Boosting with CFP-PLGA against Tuberculosis in a Goat Model

Contreras-Magallanes

Durán-Aguilar

Sosa-Gallegos

et al. 2021

Animals

View full text Add to dashboard Cite

Attempts to improve the immune response and efficacy of vaccines against tuberculosis in cattle, goats, and other animal species have been the focus of research in this field during the last two decades. Improving the vaccine efficacy is essential prior to running long-lasting and expensive field trials. Studies have shown that vaccine protocols utilizing boosting with proteins improve the vaccine efficacy. The use of polymers such as chitosan and PolyLactic-co-Glycolic Acid (PLGA) improves the immune response against different diseases by improving the interaction of antigens with the cellular immune system and modulating the host immune response. This study shows that the prime BCG vaccination, boosted with a culture filtrate protein (CFP), alone or in combination with chitosan and PolyLactic-co-Glycolic Acid (PLGA), have the potential to reduce tuberculosis (TB) dissemination by reducing the number of animals with lesions, the number of lesions per animal, and the size of the lesions in vaccinated animals, compared with those not vaccinated or those vaccinated with BCG alone. The vaccinated groups showed significantly higher Interferon-γ levels in the blood compared to the control, nonvaccinated group after vaccination, after boosting, and after the challenge with the wild-type Mycobacterium bovis strain.

show abstract

The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine

Cited by 13 publications

References 35 publications

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

Inactivated alpha toxin from Clostridium novyi type B in nano-emulsion protect partially protects Swiss mice from lethal alpha toxin challenge

Prime Vaccination with Chitosan-Coated Phipps BCG and Boosting with CFP-PLGA against Tuberculosis in a Goat Model

Contact Info

Product

Resources

About